The global market for Human Insulin Regular is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Human Insulin Regular market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Human Insulin Regular market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Human Insulin Regular market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Human Insulin Regular market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Human Insulin Regular players cover Gan & Lee Pharmaceuticals, Bioton, Novo Nordisk, Tonghua Dongbao Pharmaceutical and Shenzhen Kexing Pharmaceutical, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Human Insulin Regular market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Human Insulin Regular market, with both quantitative and qualitative data, to help readers understand how the Human Insulin Regular market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in Tons.
Market Segmentation:
The study segments the Human Insulin Regular market and forecasts the market size by Type (Insulin Glargine and Recombinant Insulin Glargine,), by Application (Hospital and Clinic.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Insulin Glargine
Recombinant Insulin Glargine
Segmentation by application
Hospital
Clinic
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Gan & Lee Pharmaceuticals
Bioton
Novo Nordisk
Tonghua Dongbao Pharmaceutical
Shenzhen Kexing Pharmaceutical
Zhuhai United Laboratories
Wanbang Biopharmaceuticals
Eli Lilly and Company
Chapter Introduction
Chapter 1: Scope of Human Insulin Regular, Research Methodology, etc.
Chapter 2: Executive Summary, global Human Insulin Regular market size (sales and revenue) and CAGR, Human Insulin Regular market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Human Insulin Regular sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Human Insulin Regular sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Human Insulin Regular market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Gan & Lee Pharmaceuticals, Bioton, Novo Nordisk, Tonghua Dongbao Pharmaceutical, Shenzhen Kexing Pharmaceutical, Zhuhai United Laboratories, Wanbang Biopharmaceuticals and Eli Lilly and Company, etc.
Chapter 14: Research Findings and Conclusion
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Human Insulin Regular Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Human Insulin Regular by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Human Insulin Regular by Country/Region, 2017, 2022 & 2028
2.2 Human Insulin Regular Segment by Type
2.2.1 Insulin Glargine
2.2.2 Recombinant Insulin Glargine
2.3 Human Insulin Regular Sales by Type
2.3.1 Global Human Insulin Regular Sales Market Share by Type (2017-2022)
2.3.2 Global Human Insulin Regular Revenue and Market Share by Type (2017-2022)
2.3.3 Global Human Insulin Regular Sale Price by Type (2017-2022)
2.4 Human Insulin Regular Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Human Insulin Regular Sales by Application
2.5.1 Global Human Insulin Regular Sale Market Share by Application (2017-2022)
2.5.2 Global Human Insulin Regular Revenue and Market Share by Application (2017-2022)
2.5.3 Global Human Insulin Regular Sale Price by Application (2017-2022)
3 Global Human Insulin Regular by Company
3.1 Global Human Insulin Regular Breakdown Data by Company
3.1.1 Global Human Insulin Regular Annual Sales by Company (2020-2022)
3.1.2 Global Human Insulin Regular Sales Market Share by Company (2020-2022)
3.2 Global Human Insulin Regular Annual Revenue by Company (2020-2022)
3.2.1 Global Human Insulin Regular Revenue by Company (2020-2022)
3.2.2 Global Human Insulin Regular Revenue Market Share by Company (2020-2022)
3.3 Global Human Insulin Regular Sale Price by Company
3.4 Key Manufacturers Human Insulin Regular Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Insulin Regular Product Location Distribution
3.4.2 Players Human Insulin Regular Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Human Insulin Regular by Geographic Region
4.1 World Historic Human Insulin Regular Market Size by Geographic Region (2017-2022)
4.1.1 Global Human Insulin Regular Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Human Insulin Regular Annual Revenue by Geographic Region
4.2 World Historic Human Insulin Regular Market Size by Country/Region (2017-2022)
4.2.1 Global Human Insulin Regular Annual Sales by Country/Region (2017-2022)
4.2.2 Global Human Insulin Regular Annual Revenue by Country/Region
4.3 Americas Human Insulin Regular Sales Growth
4.4 APAC Human Insulin Regular Sales Growth
4.5 Europe Human Insulin Regular Sales Growth
4.6 Middle East & Africa Human Insulin Regular Sales Growth
5 Americas
5.1 Americas Human Insulin Regular Sales by Country
5.1.1 Americas Human Insulin Regular Sales by Country (2017-2022)
5.1.2 Americas Human Insulin Regular Revenue by Country (2017-2022)
5.2 Americas Human Insulin Regular Sales by Type
5.3 Americas Human Insulin Regular Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Insulin Regular Sales by Region
6.1.1 APAC Human Insulin Regular Sales by Region (2017-2022)
6.1.2 APAC Human Insulin Regular Revenue by Region (2017-2022)
6.2 APAC Human Insulin Regular Sales by Type
6.3 APAC Human Insulin Regular Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Human Insulin Regular by Country
7.1.1 Europe Human Insulin Regular Sales by Country (2017-2022)
7.1.2 Europe Human Insulin Regular Revenue by Country (2017-2022)
7.2 Europe Human Insulin Regular Sales by Type
7.3 Europe Human Insulin Regular Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Human Insulin Regular by Country
8.1.1 Middle East & Africa Human Insulin Regular Sales by Country (2017-2022)
8.1.2 Middle East & Africa Human Insulin Regular Revenue by Country (2017-2022)
8.2 Middle East & Africa Human Insulin Regular Sales by Type
8.3 Middle East & Africa Human Insulin Regular Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Insulin Regular
10.3 Manufacturing Process Analysis of Human Insulin Regular
10.4 Industry Chain Structure of Human Insulin Regular
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Insulin Regular Distributors
11.3 Human Insulin Regular Customer
12 World Forecast Review for Human Insulin Regular by Geographic Region
12.1 Global Human Insulin Regular Market Size Forecast by Region
12.1.1 Global Human Insulin Regular Forecast by Region (2023-2028)
12.1.2 Global Human Insulin Regular Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Human Insulin Regular Forecast by Type
12.7 Global Human Insulin Regular Forecast by Application
13 Key Players Analysis
13.1 Gan & Lee Pharmaceuticals
13.1.1 Gan & Lee Pharmaceuticals Company Information
13.1.2 Gan & Lee Pharmaceuticals Human Insulin Regular Product Offered
13.1.3 Gan & Lee Pharmaceuticals Human Insulin Regular Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Gan & Lee Pharmaceuticals Main Business Overview
13.1.5 Gan & Lee Pharmaceuticals Latest Developments
13.2 Bioton
13.2.1 Bioton Company Information
13.2.2 Bioton Human Insulin Regular Product Offered
13.2.3 Bioton Human Insulin Regular Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Bioton Main Business Overview
13.2.5 Bioton Latest Developments
13.3 Novo Nordisk
13.3.1 Novo Nordisk Company Information
13.3.2 Novo Nordisk Human Insulin Regular Product Offered
13.3.3 Novo Nordisk Human Insulin Regular Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Novo Nordisk Main Business Overview
13.3.5 Novo Nordisk Latest Developments
13.4 Tonghua Dongbao Pharmaceutical
13.4.1 Tonghua Dongbao Pharmaceutical Company Information
13.4.2 Tonghua Dongbao Pharmaceutical Human Insulin Regular Product Offered
13.4.3 Tonghua Dongbao Pharmaceutical Human Insulin Regular Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Tonghua Dongbao Pharmaceutical Main Business Overview
13.4.5 Tonghua Dongbao Pharmaceutical Latest Developments
13.5 Shenzhen Kexing Pharmaceutical
13.5.1 Shenzhen Kexing Pharmaceutical Company Information
13.5.2 Shenzhen Kexing Pharmaceutical Human Insulin Regular Product Offered
13.5.3 Shenzhen Kexing Pharmaceutical Human Insulin Regular Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Shenzhen Kexing Pharmaceutical Main Business Overview
13.5.5 Shenzhen Kexing Pharmaceutical Latest Developments
13.6 Zhuhai United Laboratories
13.6.1 Zhuhai United Laboratories Company Information
13.6.2 Zhuhai United Laboratories Human Insulin Regular Product Offered
13.6.3 Zhuhai United Laboratories Human Insulin Regular Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Zhuhai United Laboratories Main Business Overview
13.6.5 Zhuhai United Laboratories Latest Developments
13.7 Wanbang Biopharmaceuticals
13.7.1 Wanbang Biopharmaceuticals Company Information
13.7.2 Wanbang Biopharmaceuticals Human Insulin Regular Product Offered
13.7.3 Wanbang Biopharmaceuticals Human Insulin Regular Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Wanbang Biopharmaceuticals Main Business Overview
13.7.5 Wanbang Biopharmaceuticals Latest Developments
13.8 Eli Lilly and Company
13.8.1 Eli Lilly and Company Company Information
13.8.2 Eli Lilly and Company Human Insulin Regular Product Offered
13.8.3 Eli Lilly and Company Human Insulin Regular Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Eli Lilly and Company Main Business Overview
13.8.5 Eli Lilly and Company Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. Human Insulin Regular Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Human Insulin Regular Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Insulin Glargine
Table 4. Major Players of Recombinant Insulin Glargine
Table 5. Global Human Insulin Regular Sales by Type (2017-2022) & (Tons)
Table 6. Global Human Insulin Regular Sales Market Share by Type (2017-2022)
Table 7. Global Human Insulin Regular Revenue by Type (2017-2022) & ($ million)
Table 8. Global Human Insulin Regular Revenue Market Share by Type (2017-2022)
Table 9. Global Human Insulin Regular Sale Price by Type (2017-2022) & (US$/Ton)
Table 10. Global Human Insulin Regular Sales by Application (2017-2022) & (Tons)
Table 11. Global Human Insulin Regular Sales Market Share by Application (2017-2022)
Table 12. Global Human Insulin Regular Revenue by Application (2017-2022)
Table 13. Global Human Insulin Regular Revenue Market Share by Application (2017-2022)
Table 14. Global Human Insulin Regular Sale Price by Application (2017-2022) & (US$/Ton)
Table 15. Global Human Insulin Regular Sales by Company (2020-2022) & (Tons)
Table 16. Global Human Insulin Regular Sales Market Share by Company (2020-2022)
Table 17. Global Human Insulin Regular Revenue by Company (2020-2022) ($ Millions)
Table 18. Global Human Insulin Regular Revenue Market Share by Company (2020-2022)
Table 19. Global Human Insulin Regular Sale Price by Company (2020-2022) & (US$/Ton)
Table 20. Key Manufacturers Human Insulin Regular Producing Area Distribution and Sales Area
Table 21. Players Human Insulin Regular Products Offered
Table 22. Human Insulin Regular Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Human Insulin Regular Sales by Geographic Region (2017-2022) & (Tons)
Table 26. Global Human Insulin Regular Sales Market Share Geographic Region (2017-2022)
Table 27. Global Human Insulin Regular Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global Human Insulin Regular Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global Human Insulin Regular Sales by Country/Region (2017-2022) & (Tons)
Table 30. Global Human Insulin Regular Sales Market Share by Country/Region (2017-2022)
Table 31. Global Human Insulin Regular Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global Human Insulin Regular Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas Human Insulin Regular Sales by Country (2017-2022) & (Tons)
Table 34. Americas Human Insulin Regular Sales Market Share by Country (2017-2022)
Table 35. Americas Human Insulin Regular Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas Human Insulin Regular Revenue Market Share by Country (2017-2022)
Table 37. Americas Human Insulin Regular Sales by Type (2017-2022) & (Tons)
Table 38. Americas Human Insulin Regular Sales Market Share by Type (2017-2022)
Table 39. Americas Human Insulin Regular Sales by Application (2017-2022) & (Tons)
Table 40. Americas Human Insulin Regular Sales Market Share by Application (2017-2022)
Table 41. APAC Human Insulin Regular Sales by Region (2017-2022) & (Tons)
Table 42. APAC Human Insulin Regular Sales Market Share by Region (2017-2022)
Table 43. APAC Human Insulin Regular Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC Human Insulin Regular Revenue Market Share by Region (2017-2022)
Table 45. APAC Human Insulin Regular Sales by Type (2017-2022) & (Tons)
Table 46. APAC Human Insulin Regular Sales Market Share by Type (2017-2022)
Table 47. APAC Human Insulin Regular Sales by Application (2017-2022) & (Tons)
Table 48. APAC Human Insulin Regular Sales Market Share by Application (2017-2022)
Table 49. Europe Human Insulin Regular Sales by Country (2017-2022) & (Tons)
Table 50. Europe Human Insulin Regular Sales Market Share by Country (2017-2022)
Table 51. Europe Human Insulin Regular Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe Human Insulin Regular Revenue Market Share by Country (2017-2022)
Table 53. Europe Human Insulin Regular Sales by Type (2017-2022) & (Tons)
Table 54. Europe Human Insulin Regular Sales Market Share by Type (2017-2022)
Table 55. Europe Human Insulin Regular Sales by Application (2017-2022) & (Tons)
Table 56. Europe Human Insulin Regular Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa Human Insulin Regular Sales by Country (2017-2022) & (Tons)
Table 58. Middle East & Africa Human Insulin Regular Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa Human Insulin Regular Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa Human Insulin Regular Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa Human Insulin Regular Sales by Type (2017-2022) & (Tons)
Table 62. Middle East & Africa Human Insulin Regular Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa Human Insulin Regular Sales by Application (2017-2022) & (Tons)
Table 64. Middle East & Africa Human Insulin Regular Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of Human Insulin Regular
Table 66. Key Market Challenges & Risks of Human Insulin Regular
Table 67. Key Industry Trends of Human Insulin Regular
Table 68. Human Insulin Regular Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Human Insulin Regular Distributors List
Table 71. Human Insulin Regular Customer List
Table 72. Global Human Insulin Regular Sales Forecast by Region (2023-2028) & (Tons)
Table 73. Global Human Insulin Regular Sales Market Forecast by Region
Table 74. Global Human Insulin Regular Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global Human Insulin Regular Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas Human Insulin Regular Sales Forecast by Country (2023-2028) & (Tons)
Table 77. Americas Human Insulin Regular Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC Human Insulin Regular Sales Forecast by Region (2023-2028) & (Tons)
Table 79. APAC Human Insulin Regular Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe Human Insulin Regular Sales Forecast by Country (2023-2028) & (Tons)
Table 81. Europe Human Insulin Regular Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa Human Insulin Regular Sales Forecast by Country (2023-2028) & (Tons)
Table 83. Middle East & Africa Human Insulin Regular Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global Human Insulin Regular Sales Forecast by Type (2023-2028) & (Tons)
Table 85. Global Human Insulin Regular Sales Market Share Forecast by Type (2023-2028)
Table 86. Global Human Insulin Regular Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global Human Insulin Regular Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global Human Insulin Regular Sales Forecast by Application (2023-2028) & (Tons)
Table 89. Global Human Insulin Regular Sales Market Share Forecast by Application (2023-2028)
Table 90. Global Human Insulin Regular Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global Human Insulin Regular Revenue Market Share Forecast by Application (2023-2028)
Table 92. Gan & Lee Pharmaceuticals Basic Information, Human Insulin Regular Manufacturing Base, Sales Area and Its Competitors
Table 93. Gan & Lee Pharmaceuticals Human Insulin Regular Product Offered
Table 94. Gan & Lee Pharmaceuticals Human Insulin Regular Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2022)
Table 95. Gan & Lee Pharmaceuticals Main Business
Table 96. Gan & Lee Pharmaceuticals Latest Developments
Table 97. Bioton Basic Information, Human Insulin Regular Manufacturing Base, Sales Area and Its Competitors
Table 98. Bioton Human Insulin Regular Product Offered
Table 99. Bioton Human Insulin Regular Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2022)
Table 100. Bioton Main Business
Table 101. Bioton Latest Developments
Table 102. Novo Nordisk Basic Information, Human Insulin Regular Manufacturing Base, Sales Area and Its Competitors
Table 103. Novo Nordisk Human Insulin Regular Product Offered
Table 104. Novo Nordisk Human Insulin Regular Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2022)
Table 105. Novo Nordisk Main Business
Table 106. Novo Nordisk Latest Developments
Table 107. Tonghua Dongbao Pharmaceutical Basic Information, Human Insulin Regular Manufacturing Base, Sales Area and Its Competitors
Table 108. Tonghua Dongbao Pharmaceutical Human Insulin Regular Product Offered
Table 109. Tonghua Dongbao Pharmaceutical Human Insulin Regular Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2022)
Table 110. Tonghua Dongbao Pharmaceutical Main Business
Table 111. Tonghua Dongbao Pharmaceutical Latest Developments
Table 112. Shenzhen Kexing Pharmaceutical Basic Information, Human Insulin Regular Manufacturing Base, Sales Area and Its Competitors
Table 113. Shenzhen Kexing Pharmaceutical Human Insulin Regular Product Offered
Table 114. Shenzhen Kexing Pharmaceutical Human Insulin Regular Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2022)
Table 115. Shenzhen Kexing Pharmaceutical Main Business
Table 116. Shenzhen Kexing Pharmaceutical Latest Developments
Table 117. Zhuhai United Laboratories Basic Information, Human Insulin Regular Manufacturing Base, Sales Area and Its Competitors
Table 118. Zhuhai United Laboratories Human Insulin Regular Product Offered
Table 119. Zhuhai United Laboratories Human Insulin Regular Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2022)
Table 120. Zhuhai United Laboratories Main Business
Table 121. Zhuhai United Laboratories Latest Developments
Table 122. Wanbang Biopharmaceuticals Basic Information, Human Insulin Regular Manufacturing Base, Sales Area and Its Competitors
Table 123. Wanbang Biopharmaceuticals Human Insulin Regular Product Offered
Table 124. Wanbang Biopharmaceuticals Human Insulin Regular Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2022)
Table 125. Wanbang Biopharmaceuticals Main Business
Table 126. Wanbang Biopharmaceuticals Latest Developments
Table 127. Eli Lilly and Company Basic Information, Human Insulin Regular Manufacturing Base, Sales Area and Its Competitors
Table 128. Eli Lilly and Company Human Insulin Regular Product Offered
Table 129. Eli Lilly and Company Human Insulin Regular Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2022)
Table 130. Eli Lilly and Company Main Business
Table 131. Eli Lilly and Company Latest Developments
List of Figures
Figure 1. Picture of Human Insulin Regular
Figure 2. Human Insulin Regular Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Human Insulin Regular Sales Growth Rate 2017-2028 (Tons)
Figure 7. Global Human Insulin Regular Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Human Insulin Regular Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Insulin Glargine
Figure 10. Product Picture of Recombinant Insulin Glargine
Figure 11. Global Human Insulin Regular Sales Market Share by Type in 2021
Figure 12. Global Human Insulin Regular Revenue Market Share by Type (2017-2022)
Figure 13. Human Insulin Regular Consumed in Hospital
Figure 14. Global Human Insulin Regular Market: Hospital (2017-2022) & (Tons)
Figure 15. Human Insulin Regular Consumed in Clinic
Figure 16. Global Human Insulin Regular Market: Clinic (2017-2022) & (Tons)
Figure 17. Global Human Insulin Regular Sales Market Share by Application (2017-2022)
Figure 18. Global Human Insulin Regular Revenue Market Share by Application in 2021
Figure 19. Human Insulin Regular Revenue Market by Company in 2021 ($ Million)
Figure 20. Global Human Insulin Regular Revenue Market Share by Company in 2021
Figure 21. Global Human Insulin Regular Sales Market Share by Geographic Region (2017-2022)
Figure 22. Global Human Insulin Regular Revenue Market Share by Geographic Region in 2021
Figure 23. Global Human Insulin Regular Sales Market Share by Region (2017-2022)
Figure 24. Global Human Insulin Regular Revenue Market Share by Country/Region in 2021
Figure 25. Americas Human Insulin Regular Sales 2017-2022 (Tons)
Figure 26. Americas Human Insulin Regular Revenue 2017-2022 ($ Millions)
Figure 27. APAC Human Insulin Regular Sales 2017-2022 (Tons)
Figure 28. APAC Human Insulin Regular Revenue 2017-2022 ($ Millions)
Figure 29. Europe Human Insulin Regular Sales 2017-2022 (Tons)
Figure 30. Europe Human Insulin Regular Revenue 2017-2022 ($ Millions)
Figure 31. Middle East & Africa Human Insulin Regular Sales 2017-2022 (Tons)
Figure 32. Middle East & Africa Human Insulin Regular Revenue 2017-2022 ($ Millions)
Figure 33. Americas Human Insulin Regular Sales Market Share by Country in 2021
Figure 34. Americas Human Insulin Regular Revenue Market Share by Country in 2021
Figure 35. United States Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 36. Canada Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 37. Mexico Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 38. Brazil Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 39. APAC Human Insulin Regular Sales Market Share by Region in 2021
Figure 40. APAC Human Insulin Regular Revenue Market Share by Regions in 2021
Figure 41. China Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 42. Japan Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 43. South Korea Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 44. Southeast Asia Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 45. India Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 46. Australia Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 47. Europe Human Insulin Regular Sales Market Share by Country in 2021
Figure 48. Europe Human Insulin Regular Revenue Market Share by Country in 2021
Figure 49. Germany Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 50. France Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 51. UK Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 52. Italy Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 53. Russia Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 54. Middle East & Africa Human Insulin Regular Sales Market Share by Country in 2021
Figure 55. Middle East & Africa Human Insulin Regular Revenue Market Share by Country in 2021
Figure 56. Egypt Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 57. South Africa Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 58. Israel Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 59. Turkey Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 60. GCC Country Human Insulin Regular Revenue Growth 2017-2022 ($ Millions)
Figure 61. Manufacturing Cost Structure Analysis of Human Insulin Regular in 2021
Figure 62. Manufacturing Process Analysis of Human Insulin Regular
Figure 63. Industry Chain Structure of Human Insulin Regular
Figure 64. Channels of Distribution
Figure 65. Distributors Profiles
Global Graphitized Carbon Black (GCB) Ma..
Graphitized carbon black is a black particle that can be use..
+16467917070US (Toll Free)